Table 1.
Socio-demographic and clinical characteristics of respondents across countries (N = 45). Data is reported as n (%) or mean ± SD
| Variables | Overall (n = 45) |
UK (n = 10) |
Germany (n = 10) |
France (n = 8) |
Spain (n = 10) |
Italy (n = 7) |
|---|---|---|---|---|---|---|
| Gender | ||||||
| Man | 22 (49.0) | 7 (70.0) | 5 (50.0) | 1 (13.0) | 5 (50.0) | 4 (57.0) |
| Woman | 23 (51.0) | 3 (30.0) | 5 (50.0) | 7 (87.0) | 5 (50.0) | 3 (43.0) |
| Marital state | ||||||
| Yes | 33 (73.0) | 9 (90.0) | 6 (60.0) | 5 (63.0) | 6 (60.0) | 7 (100.0) |
| No | 12 (27.0) | 1 (10.0) | 4 (40.0) | 3 (37.0) | 4 (40.0) | – |
| Age | ||||||
| Mean ± SD | 62.3 ± 13.2 | 70.3 ± 7.5 | 60.3 ± 10.5 | 48.5 ± 11.1 | 71.1 ± 11.8 | 60.6 ± 13.9 |
| Missing | 3 (30.0) | |||||
| Education levela | ||||||
| Low | 10 (22.0) | 4 (40.0) | – | – | 5 (50.0) | 1 (14.3) |
| Medium | 10 (22.0) | 2 (20.0) | 3 (30.0) | 3 (37.5) | 1 (10.0) | 3 (42.9) |
| High | 25 (56.0) | 4 (40.0) | 7 (70.0) | 5 (62.5) | 4 (40.0) | 3 (42.9) |
| Employment status | ||||||
| Employed (full/part-time) | 3 (6.7) | 3 (30.0) | 5 (50.0) | 7 (87.5) | 3 (30.0) | |
| Retired | 20 (44.4) | 7 (70.0) | 4 (40.0) | – | 5 (50.0) | 3 (42.9) |
| Unemployed | 21 (46.7) | – | 1 (10.0) | 1 (12.5) | 1 (10.0) | 4 (57.1) |
| Missing | 1 (2.2) | – | – | – | 1 (10.0) | – |
| Annual household income (€) | ||||||
| 0–15,000 | 7 (15.6) | 1 (10.0) | 1 (10.0) | 1 (12.5) | 2 (20.0) | 2 (28.6) |
| 15,001–25,000 | 7 (15.6) | – | 2 (20.0) | 1 (12.5) | 2 (20.0) | 2 (28.6) |
| 25001–50,000 | 12 (26.7) | 5 (50.0) | 3 (30.0) | 1 (12.5) | 2 (20.0) | 1 (14.3) |
| 50,001+ | 7 (15.6) | 1 (10.0) | 1 (10.0) | 3 (37.5) | 1 (10.0) | 1 (14.3) |
| Unknown | 11 (24.4) | 3 (30.0) | 3 (30.0) | 2 (25.0) | 2 (20.0) | 1 (14.3) |
| Missing | 1 (2.2) | – | – | – | 1 (10.0) | – |
| OAC therapy | ||||||
| Total no. of patients on VKA | 26 (57.8) | 6 (60.0) | 6 (60.0) | 4 (50.0) | 5 (50.0) | 5 (71.4) |
| Warfarin | 10 (22.2) | 6 (60.0) | – | – | – | 4 (57.1) |
| Acenocoumarol | 6 (13.3) | – | – | – | 5 (50.0) | 1 (14.3) |
| Phenprocoumon | 6 (13.3) | – | 6 (60.0) | - | – | – |
| Fluindione | 4 (8.9) | – | - | 4 (50.0) | – | – |
| Total no. of patients on DOAC | 19 (42.2) | 4 (40.0) | 4 (40.0) | 4 (50.0) | 5 (50.0) | 2 (28.6) |
| Dabigatran | 7 (15.6) | 1 (10.0) | 3 (30.0) | 1 (12.5) | 1 (10.0) | 1 (14.3) |
| Rivaroxaban | 7 (15.6) | 1 (10.0) | 1 (10.0) | 2 (35.0) | 3 (30.0) | - |
| Apixaban | 5 (11.1) | 2 (20.0) | – | 1 (12.5) | 1 (10.0) | 1 (14.3) |
| Time period on OAC therapy | ||||||
| < 1 year | 19 (42.2) | 5 (50.0) | 1 (10.0) | 4 (50.0) | 3 (30.0) | 6 (85.7) |
| 1–5 years | 9 (20.0) | – | 6 (60.0) | 3 (37.5) | – | – |
| > 5 years | 15 (33.3) | 4 (40.0) | 3 (30.0) | 1 (12.5) | 6 (60.0) | 1 (14.3) |
| Missing | 2 (4.4) | 1 (10.0) | – | – | 1 (10.0) | – |
DOAC direct (non-VKA) oral anticoagulant, OAC oral anticoagulant, SD standard deviation, VKA vitamin K antagonist
aLow educational level: lower technical and vocational training and lower general secondary education; medium educational level: intermediate vocational training and advanced secondary education; high educational level: higher vocational education and university